Many pharmaceuticals and illicit drugs are classified as controlled substances. For added convenience, certified reference materials (CRMs) and reference materials (RMs) of numerous pharmaceuticals, diagnostic biomarkers, and illicit drugs of abuse as well as their internal standards, metabolites, impurities, and degradants are supplied as DEA-exempt solutions. These CRMs and RMs are suitable for a wide variety of chromatographic and mass spectrometry-based testing applications such as clinical toxicology, forensic analysis, pharmaceutical testing and research, clinical diagnostic testing, cannabis profiling and potency determination, sports/anti-doping testing, pain prescription monitoring, and employee drug screening.
The Cerilliant® portfolio includes a wide range of certified reference materials from various drug classes that are manufactured in facilities accredited with ISO Guide 34 and ISO/IEC 17025 and ISO 9001. Each of our Cerilliant® pharmaceutical reference materials are supplied with a comprehensive certificate of analysis (CoA), which is among the most extensive in the industry.
For the analysis of illegal drug substances in forensic and clinical laboratories, the availability of reliable certified reference materials is crucial. We offer an extensive portfolio of reference materials of drugs of abuse, including cannabinoids, opioids, cocaine analogs, barbiturates, amphetamines, steroids and other chemical classes for all your illicit drug testing.
Diagnostic biomarkers are used to diagnose and understand the progress of a disease. We provide a broad spectrum of certified reference materials suitable for diagnostic laboratory developed test applications. These applications range from clinical and diagnostic testing, target analysis to identify novel biomarkers of clinical relevance and pharmaceutical research of disease targets.
Investigación. Desarrollo. Producción.
Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos
© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.